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Abstract
Background: Multiple sclerosis (MS) is a disease of central nervous system that causes the removal of fatty myelin
sheath from axons of the brain and spinal cord. Autoimmunity plays an important role in this pathology outcome
and body’s own immune system attacks on the myelin sheath causing the damage. The etiology of the disease is
partially understood and the response to treatment cannot easily be predicted.
Results: We presented the results obtained using 8 genetically predisposed randomly chosen individuals
reproducing both the absence and presence of malfunctions of the Teff-Treg cross-balancing mechanisms at a
local level. For simulating the absence of a local malfunction we supposed that both Teff and Treg populations
had similar maximum duplication rates. Results presented here suggest that presence of a genetic predisposition is
not always a sufficient condition for developing the disease. Other conditions such as a breakdown of the
mechanisms that regulate and allow peripheral tolerance should be involved.
Conclusions: The presented model allows to capture the essential dynamics of relapsing-remitting MS despite its
simplicity. It gave useful insights that support the hypothesis of a breakdown of Teff-Treg cross balancing
mechanisms.
Background
Multiple sclerosis (MS) is a disease of central nervous
system. The disease causes the removal of fatty myelin
sheath from axons of the brain and spinal cord resulting
reduced communication among nerve cells. Autoimmu-
nity plays an important role in the disease outcome and
body’s own immune system attacks on the myelin sheath
causing the damage. Several genetic factors including
HLA-DR15, HLA-A*02 and HLA-DRB1*1501 [1,2] are
documented to relate with MS.
MS concordance rate is greater in fraternal twins than
for siblings [3,4] showing the involvement of genetic
factors. Besides genetic factors, environmental factors
are also considered to have a significant role e.g.
Epstein-Barr viral infection [5-7] and some dietary
factors. Vitamin D and turmeric play a protective role in
MS and neurodegeneration.
Turmeric protects brain from neurodegeneration and
vitamin D is considered one of the most important fac-
tors to prevent MS [8]. Some also considered that there
is a significant role of epigenetic factors [9] in the disease
occurrence. The symptoms of the disease includes weak-
ness of limbs, vision problems, slurred speech, fatigue,
dizziness, difficulty in muscle coordination and losing
strength and uncontrolled bodily functions. The disease
occurs mostly in the age of 20-40 and women are affected
twice compared to men.
The etiology of the disease is partially understood and
the response to treatment cannot easily be predicted.
Symptoms of MS are apparently unpredictable and may
vary from person to person, which represents one of the
most disturbing aspects reported by patients. Even in the
same patient, symptoms and treatment responses may vary
from time to time. Therefore, establishing the prognosis of
* Correspondence: mpennsi@dmi.unict.it
1Department of Mathematics and Computer Science, University of Catania,
Italy
Full list of author information is available at the end of the article
Pennisi et al. BMC Bioinformatics 2013, 14(Suppl 16):S9
http://www.biomedcentral.com/1471-2105/14/S16/S9
© 2013 Pennisi et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
the disease and predicting the response to therapy at the
individual level is a real challenge. Environmental factors
(e.g. vitamin D levels, antibodies against Epstein-Barr
Virus, smoking), pharmaceutical therapy (immunotherapy)
and behavioral factors (stress) may have a significant effect
on the clinical course and pathway of the disease.
Currently, more than 400,000 patients suffer from MS
in Europe; for the US a number between 250,000 and
400,000 is discussed. MS has a prevalence that ranges
between 2 and 150 per 100,000 individuals, depending on
the country or specific population [10].
Relapsing remitting multiple sclerosis (RRMS) is the
most prevalent type of MS, around 90% of all the patients
have RRMS [11], in which disease relapse and remission
occurs after a certain time period. Relapse is a term
which defines a period of worsening of disease activity, it
could be development of new symptoms or reoccurrence
of previous symptoms with or without increased severity.
Remission is defined as complete or partial recovery of
the symptoms following relapse. The occurrences of the
relapse vary from mild to severe based on the course and
history of the disease. It is also common to have a pro-
gressive phase of the disease and a large study showed
that around 80% of cases followed by chronic progression
within 20 years [12]. Disease progression can be observed
by different means including Expanded Disability Status
Score (EDSS), Magnetic Resonance Imaging (MRI) lesion
and with other physical test including timed 25-Foot
Walk, MS Walking Scale-12.
Besides those tests clinical relapses are also considered a
mean to see whether patient is improving after given a
certain drug or the conditions are getting worse. In some
cases relapse was considered as an indication of local
inflammatory event [13] but it was shown that the relapse
rate decreases as the disease progression [14,15]. Moreover
brain compensatory mechanisms can show a recovery in
neurologic capabilities (remitting phase) even if unrecover-
able neural damage has occurred [16].
T-cell plays a major role in disease progression and it is
documented that regulatory T-Cell decreases in the per-
ipheral blood when relapse occurs. On the contrary, num-
ber of helper T-cells increases in the spinal fluid. It is also
hypothesized that homeostasis of regulatory T cells (Treg)
and effectors T cells (Teff) play a crucial part in preventing
autoimmunity [17-19]. In particular, lack of functionality
or deficiency of Treg may entitle negative effects in the
peripheral tolerance mechanisms that are believed to con-
trol activation and proliferation of Teff [20].
MS is a complex disease involving many biological
scales, from molecular scales to organs, and environmen-
tal factors. In this scenario mathematical/computational
models are requested both in knowledge discovery to
perform in silico experiments and suggest preclinical
experiments and in clinical scenarios to help Medical
Doctors to envisage the correct therapy for their patients.
To build a mathematical/computational model one
can use a variety of different techniques [21]. Among
these, Agent Based Modeling (ABM) look to be one of
the most appropriate to describe complex systems in a
flexible way.
In the present paper we propose the first attempt to
model MS using ABM. To our best knowledge only Read
et al. presented in [22] an ABM for modeling Experimental
Autoimmune Encephalomyelitis (EAE), a mouse proxy
for MS.
Our model is aimed to describe RRMS taking into
account the cross-regulation between the two cells popu-
lations, coupled with an external agent (such as the
Epstein-Barr Virus (EBV)) supposed as the cause of
chronic inflammation, in order to see whether such sys-
tem is able to show stable oscillatory behaviors in healthy
patients, and presence of unrecoverable neural damage in
patients with a malfunction in the cross-regulation
mechanisms between Teff and Treg.
The present model is rather simple as include only three
classes of entities. However, as mentioned before, ABM
models are very flexible and the present model can be
expanded to include a more detailed description of the
immune system entities and functions or environmental
factors (i.e., Vitamin D).
Materials and methods
Biological hypotheses and conceptual model
To model and simulate RRMS we made some hypotheses
based on most recent experimental evidence. The first
hypothesis is about the presence of a mechanism of com-
petition and cross regulation between Treg and Teff
cells. In particular we supposed that Teff are down regu-
lated by Treg cells and Treg cells are upregulated by Teff
cells. Many known mechanisms induce the inhibition of
Teff by Treg, for example cell-to-cell contact inhibition
[23] and secretion of immunosuppressive cytokines [24].
On the other hand, it has been observed that Treg benefit
of a positive feedback which promotes proliferation [25]
coming from signals of Teff cells [19].
This cross regulation between the two populations
reminds to the famous predator-prey (Lotka-Volterra)
equations. In this dynamical system, the population of prey
is represented by activated Teff cells that use available food
resources (represented by myelin and cerebral tissues) to
grow. On the other hand the population of predators
(represented by activated Treg) try to catch and suppress
them.
Another biological hypothesis that has been carried
into account is represented by the fact that an environ-
mental agent such as a virus causes the inflammation.
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In particular the EBV satisfies all requirements as candi-
date trigger: it is ubiquitous in nature, establishes a life-
long dormant infection with activation that causes
continuous virus production, and modulates the human
immune system [26]. Many potential mechanisms have
been identified to be responsible for the association of
EBV infection with MS [26]. Among these we took into
account the possibility that EBV-specific T cells could
cross-react with autoantigens expressed in the CNS (such
as the myelin basic protein or MBP) and attack the mye-
lin sheath of axons.
We further supposed that there exists a correlation
between the presence of a relapse and neural damage.
Some recent studies showed in fact that some biomar-
kers of axonal damage (NFL) and demyelination (MBP)
were increased in all RR MS patients [27].
Even if the appearing of a disability cannot be always
directly correlated with an inflammation in the central
nervous system, many studies using magnetic resonance
spectroscopy suggest that axonal loss begins at the onset of
the disease and show the presence of brain atrophy in the
earliest stages of MS. Moreover it has been shown that
brain atrophy increases during the relapsing-remitting dis-
ease stage without concurrent disability progression,
suggesting that compensatory mechanisms may allow the
recovery of neurologic capabilities, even if brain unrecover-
able tissue loss during the early stages of the disease
occurred [16]. We should note that the observation of (two
or more) lesions in different parts of the CNS using mag-
netic resonance imaging techniques represents nowadays
one of the necessary conditions associated with the diagno-
sis of MS. To this end we supposed to associate the
appearing of a relapse with the presence of new unrecover-
able neural damage.
Another hypothesis that has been taken into account
is given by the fact that, in susceptible individuals, self-
reactive T cells are able to pass the thymus selection and
are thus present in the blood periphery [11]. Many stu-
dies have confirmed the presence of some genetic predis-
position by individuating multiple specific genes that
entitle higher risks of developing MS. Among these we
recall the HLA-DR and -DQ genes and the HLA-DR15
haplotype in Caucasians [28]. The presence of some
breakdown in the peripheral immune tolerance mechan-
isms that allows the activation of Teff [20,29-32] repre-
sents another condition that has been taken into
consideration. This scenario has been observed both in
mice [33,34] and in humans [35,36]. Furthermore it has
been observed in MS and type 1 diabetic patients the pre-
sence of a dysfunction of the Treg function and an imbal-
ance in Teff-Treg cross-regulation mechanisms [37,38].
This has been modeled by supposing that Treg had lower
duplication rates than Teff in hill patients.
Agent based modeling approaches
Agent-based modeling approaches simulate the behavior of
autonomous entities (this could be buyers in economic
models, in our case the autonomous entities are cells). The
models simulate the simultaneous operations and interac-
tions of multiple agents (in our case cells and molecules),
in an attempt to re-create and predict the appearance of
complex phenomena (in our case: cellular interactions in
neuroinflammation and neurodegeneration). The process
is one of emergence from the lower (micro: cell) level of
systems to a higher (macro: organ) level.
Agent dynamics can be described as a function of time,
position and internal states (i.e. age) of every agent. Inter-
action (i.e. cooperation or competition) with nearby agents
modifies the dynamics of interacting agents. Emerging
complex behavior is obtained by taking into account all
the microscopic stochastic interactions of all agents which
cooperate and/or compete to achieve a global solution.
ABMs naturally handle entity heterogeneity and physical
space, and suffer less from the issue of directly designed
dynamics. Moreover its easy to describe complex beha-
viors just because specifying agent rules is intuitively
straightforward. On the other and, ABM lack of a solid
mathematical basis that could be used to easily study
asymptotic behaviors and provide further mathematical
analysis and they need massive computational resources in
order to allow (near-to) natural scale simulations. High
effective parallel algorithms or platforms to support
such approaches represent one of the next future major
challenges.
ABMs have been successfully used for simulating many
pathologies such as HIV virus [39-41], mammary carci-
noma and lung metastases [42,43], the cell-based immune
response to cancer cell antigen presentation [44] and
atherosclerosis [45]. We considered the agent-based
modeling technique the ideal approach to model cellular
interactions as they occur in neuro-inflammatory and
neuro-degenerative processes such as MS.
An easy way to implement an ABM is to use of an agent
based oriented programming language. One of these lan-
guages is represented by NetLogo. NetLogo is a program-
ming language and integrated modeling suite totally
oriented and devoted to ABMs. It was developed in Java
by Uri Wilensky in 1999 and it has been continuously
updated ever since. It features an extensive documentation
and multiple tutorials and a worldwide community that
furnishes great support. It is free and open-source and
cross-platform. NetLogo represents a good choice to simu-
late multi-agents, networks and complex dynamical sys-
tems [46]. Another choice for developing the ABM model
was represented by the use of a general purpose computer
language, for example ANSI C. We used such an approach
several times [47-52]. However, NetLogo allowed a faster
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developing of the model as, at this stage, we did not man-
age a large quantity of details, entities and interactions.
Moreover models developed in NetLogo can be easily
shared as Java applets i.e., they are able to be run in almost
(if not all) computer platforms. Finally NetLogo models
take advantage of the graphical interface that easily allows
the plot of various entities dynamics. Of course the imple-
mentation of a more detailed model would require the
flexibility and the speed given by the use of a pure pro-
gramming language. For huge simulations, parallel com-
puting is highly advisable and the use of a programming
language as C is imperative.
The model
Preliminary considerations
In order to simulate RRMS we used Netlogo agent based
modeling framework. To this end we built a model that
uses a grid of 51x51 cells (namely patches) to simulate a
small portion of white matter. Every patch is colored in
light gray and is initialized at the beginning of the simula-
tion with non-zero quantity init_mye of myelin that cov-
ers the axons in healthy patients. In order to simulate
recoverable and unrecoverable damage, we supposed that
every patch that is attacked by Teff loses a given value of
myelin ate_mye, in this case the patch is colored in dark
gray to simulate the presence of damage. If the patch still
contains a quantity of myelin that is greater than zero,
the damage can be recovered (recoverable damage) at
every time-step with a given rate rec_mye up to the initial
quantity init_mye; otherwise (i.e. the remaining quantity
of myelin is zero) the patch is colored in black and the
damage cannot be recovered anymore (unrecoverable
damage). This mechanism is supported by several facts in
reality. Resident oligodendrocytes (if still present) are
activated and are able to restore the lost percentage of
myelin [11]. We used a time-step of Δ(t) = 2.4 hours. We
chose such a time-step because it allowed to keep, from a
temporal point of view, a good degree of granularity that
enabled to simulate singular relapses, yet allowing to
reproduce, using reasonable computational resources, the
progress of the disease in a time-window of five years
(18250 time steps).
The model supposes the presence of three kinds of agents
(called turtles in Netlogo): auto reactive effector T cells
(Teff), regulatory T cells (Treg), and EBV (Viruses). All
agents are introduced with a life counter randomly set to a
value between [1; 2*hlife], where hlife (Δ(t)-1) represents the
mean half life of involved agents. The life counter is usually
decremented by 1 at every time-step for all agents. All
agents can move and interact during the simulation at
every time-step. Movement and interaction rules are
described in the next sections. We used a Von Neumann
neighborhood [53].
Introduction of all agents inside the simulation is done
using stochastic pulse trains instead of Gaussian white
noise. As suggested in [54], the introduction of agents
using stochastic impulses is advisable in order to gain
more realistic and general understanding of the effect of
environmental fluctuations leading to extinction of the
species. Gaussian white noise assumes the presence of a
continuous perturbation, and this is not in line with thy-
mic selection where the selection newborn resting T cells
with a given specificity can be seen a sequence of discrete
stochastic events. As in the paper by Vélez de Mendizábal
et al. [13], both the introduction of resting Teff and Treg
is done using trains of 100 randomly distributed impulses
per year. This reflected the fact that the generation of a
given self-reacting T-cells can be seen as a consequence of
unrelated stochastic events [55]. Also viruses are intro-
duced with the same technique.
We would note here that we actually modeled a single
organ representing a piece of brain tissue, instead of
modeling all the organs and spatial mechanisms (i.e.
lymphnodes, central nervous system, blood brain barrier
so on) that are involved in the development of MS. This
is clearly a simplification of the reality but it did not
represent a problem since in the present model activated
Teff and Treg are the sole agents that actively interact in
and with the brain tissues. The other agents (resting Teff,
resting Treg, and viruses) do not interact with the under-
lying patches (which contain the myelin) and thus it is
possible to imagine that all the interactions involving
such agents occur elsewhere.
Logic implemented in the prototype
Due to a genetic predisposition, self-reactive resting Teff
and Treg cells are introduced into the system randomly
using stochastic pulse trains. The presence of an external
factor such as the presence of EBV latent infection can,
through mimicry, cause activation of both Teff and Treg
cells. Activated Teff cells can then attack myelin in the
brain and duplicate, activated Treg will try to catch active
Teff and stop their activities, thus they receive a positive
feedback and will duplicate. In Figure 1 we show the con-
ceptual model that implements this logic.
States and Transitions
Both Teff and Treg cells have two internal states: (a) rest-
ing and (b) activated. All cells are introduced into the
simulation in resting state. Resting cells cannot duplicate,
activated cells can. We suppose for now that viruses have
no internal states and are used to trigger the activation of
auto reactive T cells through mimicry [56].
All local state transitions entitle global evolving of the
system. These state transitions can be described locally as
events that occur and modify the state of one or more
agents. They mainly happen two reasons: natural state-
transitions (i.e. death) and interactions among agents.
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Both the transitions are presented next, as follows:
• Death: At any time step the life counter of any
entity is decremented by 1. If the life counter of an
agent reaches 0 then the agent is removed from the
simulation.
• Movement: At any time step all turtles can move in
a patch in their neighbourhood chosen at random.
• Introduction of new agents: As already discussed,
at every time-step 3 bernoulli events (for Teff, Treg,
and viruses) with a probability p = 100/365 are simu-
lated in order to decide whether introduce new turtles
or not (stochastic pulse trains). If success occurs the
new turtles are introduced into the simulation. Treg
and Teff are introduced in resting state.
• Myelin attack by active Teff: If active Teff is in a
patch with a nonzero quantity of myelin then the Teff
will attack the myelin causing axonal damage and
then the quantity of myelin will be lowered by ate
mye; the Teff will be eligible to duplicate. If the
quantity of myelin reaches 0 then the Teff will be not
able to duplicate.
• Duplication of active Teff: If a Teff successfully
causes axonal damage, it will be stimulated to dupli-
cate. Duplication is modeled as a stochastic bernoulli
process. In other words the Teff will have a probability
to duplicate pe and to do not duplicate equal to 1 - pe.
The probability pe is calculated for every duplication
process according to the following law:




Treg here +mean Tregs
where myelin indicates the quantity of myelin in the cur-
rent patch, eff_dup is a duplication constant representing
the maximum duplication rate of Teff, mean_Tregs is a
given threshold and Treg_here is the number of Tregs in a
given radius Treg_radius. The term myelin
2
init mye2 gives higher
probabilities to duplicate if the patch has higher quantities
of myelin, whereas the term mean TregsTreg here+mean Tregs is used to
Figure 1 Conceptual model. Figure shows the logic implemented into the model, including the genetic predisposition in developing the
pathology (i.e. thyms selection of self-reactive clones), the presence of an external trigger (i.e. EBV), the supposed malfunction of the Treg-Teff
mechanism, and the effects caused by the malfunction (i.e. neural damage due to myelin loss). Self-reactive resting Teff and Treg cells are introduced
by Thymus selection. An external factor such as EBV latent infection can cause activation of both Teff and Treg cells. Activated Teff cells can then
attack myelin causing damage in the brain and duplicate, activated Treg will downregulate Teff receiving a positive feedback from that. reversible
damage can be recovered.
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model the down-regulation of Teff duplication rates by
Treg actions. As discussed before, Tregs can inhibit Teff
duplication through cytokines signaling. We did not
model explicitly these cytokines, but we took into account
the possibility an active Treg can release them. So, there is
a high number of Tregs in a given radius, then the possibi-
lity of having such cytokine inhibitors will be higher and
so this will lower the probability of duplicating of Teff.
At this point If the number of agents is below a given
threshold patch_density then the turtle will duplicate; the
turtle will move to a patch in the neighborhood and a new
duplication probability pe will be calculated otherwise. If
duplication occurs the duplicating Teff will have its life
counter reduced by half. The newborn Teff will be already
active and will be positioned in a patch in the neighbor-
hood chosen at random.
• Active Treg - Active Teff interaction: If an active
Treg finds an active Teff in a neighborhood of radius
treg_radius the Treg will move towards Teff and will
suppress it. Then the Treg will be eligible to duplicate.
• Duplication of active Treg: If a Treg successfully
suppresses a Teff, it will be stimulated to duplicate.
Even Treg duplication is modeled as a stochastic ber-
noulli process. Treg will have a probability to duplicate
pt and to do not duplicate equal to 1 - pt. where pt is a
duplication constant representing the maximum dupli-
cation rate of Treg. If the number of agents is below a
given threshold patch_density then Treg will duplicate;
the Treg will move to a patch in the neighborhood
and a new duplication probability pt will be calculated
otherwise. If duplication occurs the duplicating Treg
will have its life counter reduced by half. The newborn
Treg will be already active and will be positioned in a
patch in the neighborhood chosen at random.
• Resting Teff - virus interaction: If a resting Teff
encounters a virus in a neighborhood of radius virus_-
radius the Teff switches its internal state to active. The
virus will disappear from the simulation. This interac-
tion is used to mimic the activation of auto reactive
effector T cells by antigen presenting cells (APC) that
present EBV epitopes and it is due antigenic mimicry
mechanisms described earlier. We did not actually
model APC since at the present time their presence in
the model is not strictly fundamental. Successive ver-
sions of the model will cover this.
• Resting Treg - virus interaction: If a resting Treg
encounters in virus in the neighborhood of radius virus
radius the Teff switches its internal state to active. The
virus will disappear from the simulation. This interac-
tion is used to mimic the activation of auto reactive
regulatory T cells. Even in this case the same consid-
erations made for Resting Teff - virus interaction hold.
Simulation of different individuals
In order to simulate different patients we initialized the
Netlogo pseudo-random number generator with different
seeds for every simulation. When the pseudo-random
number generator is initialized with a given seed it will
generate a (replicable) chain of random numbers that are
used to decide the occurrence (or not) of stochastic events.
So every seed will entitle a completely different sequence
of events for each simulation and two simulations that are
started with different seeds usually enable totally different
observable behaviors and results.
Results and discussion
As we discussed in section Materials and methods, we
supposed that the appearing of a relapse and the presence
of new unrecoverable neural damage are correlated [16].
In this paper we present the results obtained using
8 genetically predisposed randomly chosen individuals.
We reproduced both the absence and presence of mal-
functions of the Teff-Treg cross-balancing mechanisms at
a local level. For simulating the absence of a local malfunc-
tion we supposed that both Teff and Treg populations had
similar maximum duplication rates. In other words we set
the maximum duplication rate of Teff eff_dup and the
duplication rate of Treg pt to the same value, so both the
cells populations have the same maximum duplication
rates. We further supposed that the breakdown of the
cross regulation mechanism is due to a lower duplication
rate pt of Treg. In Table 1 we reassumed the most impor-
tant parameters used for the simulations.
We also tested the model by simulating 100 randomly
chosen virtual patients (data not shown) in both the hill
and the healthy scenarios by setting [eff_dup = 0.1; pt =
0.025] and [eff_dup = 0.1; pt = 0.1], respectively. We took,
as outcome of the experiments, the total damage at the
end of the simulations for both the scenarios. Median
values of the final total damage were 77268 for the hill
sample and 5357 for the healty sample. Non parametric
Kolmogorov-Smirnov two samples goodness-of-fit test
gave as result a maximum difference between the cumula-
tive distributions D = 0.7500 with a corresponding p-value
of: 0.000, thus suggesting that the two samples are unlikely
to be drawn from the same distribution (i.e., they are sta-
tistically different).
In Figure 2 the behavior of Teff, Treg and viruses vs
time for all the presented individuals in absence of mal-
functions of the Teff-Treg cross-balancing mechanisms is
showed. The number of Teff (in red) has some spikes at
different time intervals in all plots. This indicates that in
some cases, due to the stochasticity in the introduction
of newborn cells, self-reactive Teff may initially escape
from Treg control (blue lines) and can be activated due
to mimicry, duplicate and try to attack myelin. However
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activated Treg are able to counterbalance Teff actions
maintaining immune homeostasis. This is visible in
Figure 4 where we show the levels of damage (recover-
able, unrecoverable and total) for all the simulations. In
this figure it is possible to see the presence of some
spikes in the recoverable damage plots (blue lines) that
obviously correspond to the spikes seen in Figure 2.
However such damage is usually recovered and at the
end of the simulation almost no unrecoverable damage
(red lines) arises. Figure 6 presents the spatial plots at the
end of every simulation (after 5 years) in healthy patients.
The plots confirm the observations that came from
Figure 2, as almost no black patches (which indicate the
presence of some scarring or lesions) are present.
In Figure 3 we show the behavior of Teff, Treg and
viruses vs time for all the individuals in the case of mal-
functions of the Teff-Treg cross-balancing mechanisms.
Similarly to what has been observed in Figure 2, all plots
show some spikes in the Teff behaviors (red lines). How-
ever in this case the spikes are more numerous and reach
higher values thus suggesting that, due the malfunction
in the regulatory mechanisms, Teff can be easily activated
and cause brain damage. In this case Treg are not always
able to contrast Teff actions and maintain homeostasis,
and this is visible in Figure 5 where the levels of damage
are shown for all the simulations. In this case the spikes
in the reversible damage plots (blue lines) are higher and
bigger in number. It is also possible to observe the
appearing of unrecoverable damage that indicates the
appearing MS plaques and to see how the sum of both
(total damage, black plots) mimics the typical relapsing-
remmiting dynamics observed in MS. Presence of scar-
ring can be also seen in Figure 7 where the spatial plots
for all individuals are presented at the end of 5 years. In
all plots it is possible to see many black areas that indi-
cate unrecoverable damage and thus the presence of
lesions and scarring that may be correlated with relapses
and appearing of inability.
We also observed that (data not shown), in some cases
(for some seeds) a decrease in the Teff or an increase Treg
proliferation does not always entitle less severe relapses
and, as a matter of fact, it could produce more severe
relapses. This is mainly due to the stochasticity of the
model. It may happen that the stochastic injection of new
resting Teff may be not shortly followed by an equivalent
injection of Treg, thus creating a temporary disequilibrium
between the two populations which would entitle some
neural damage even in potential healthy patients.
Results presented here suggest that presence of a
genetic predisposition is not always a sufficient condition
for developing the disease. Other conditions such as a
breakdown of the mechanisms that regulate and allow
peripheral tolerance should be involved. This has also
been observed in [13]. In our case we supposed that a
malfunctioning of self-reactive regulatory T cells caused
by lower duplication rates was the cause. Of course other
conditions may be the cause of such a malfunctioning.
Moreover we observed that in the simulations of hill
patients relapses mainly occur in the first half of the
simulation rather than in the second half (see, for exam-
ple, Figure 5, plots (a),(c),(d) and (e)). This could be in
line with clinical observations which showed that the
relapse rate tends to decrease as the disease progression
[14,15].
Conclusions
In this work, we presented the first simple model of MS
using agent based modeling approach. It shows the main
behavior of this neural disease i.e., the relapse-remitting
one. Compared to the real biological scenario, the model
is naive, but takes into account the main entities involved
at cellular level in the pathogenesis of MS. It allows to
grasp how the role of regulatory vs effectors cells and
their internal dynamics are crucial in the understanding
the evolution of neural damage in the progression of the
pathology. We will continue working with this model to
Table 1 Principal model parameters
Parameter Value (estimate) Meaning
treg_radius 3 max visibility radius of Treg
eff_dup 0.1
(range 0.025 - 0.2) Δ(t)-1[13]
max. duplication rate of Teff
init_mye 100 initial quantity of myelin per patch
eat_mye 5 quantity of myelin destroyed by Teff
pt 0.1 in healthy patients
0.025 in hill patients (range 0.025 - 0.2) Δ(t)-1[13]
max. duplication rate of Treg
patch_density 3 max. no of entities per patch allowed to have duplication
Teff_life 60
(range 50-70) [58] Δ(t)
Teff mean half-life
Treg_life 60
(range 50-70) [58] Δ(t)
Treg mean half-life
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Figure 2 Entity behaviors vs time in healthy patients. Simulation of eight randomly-selected healthy virtual patients. We suppose that both
Treg and Teff have similar duplication rates. Simulation time is 5 years (18250 time-steps). Red lines represent activated Teff behaviors, blue lines
represent activated Treg behaviors and green lines viruses behaviors. In this case the number of Teff peaks is relatively small due to the action of
regulatory mechanisms. This would entitle lower probabilities of having unrecoverable damage.
Pennisi et al. BMC Bioinformatics 2013, 14(Suppl 16):S9
http://www.biomedcentral.com/1471-2105/14/S16/S9
Page 8 of 14
Figure 3 Entity behaviors vs time in hill patients. Simulation of eight randomly-selected hill virtual patients. We suppose that the breakdown
of the cross regulation mechanism is due to a lower duplication rate pt of Treg. Simulation time is 5 years (18250 time-steps). Red lines
represent activated Teff behaviors, blue lines represent activated Treg behaviors and green lines viruses behaviors. In this case the number of
Teff peaks is higher. Moreover each peak reaches higher values in respect to healthy patients, thus indicating that higher numbers of self-
reactive Teff may entitle higher probabilities of having unrecoverable damage.
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Figure 4 Damage progression vs time in healthy patients. Simulation of eight randomly-selected healthy virtual patients. Simulation time is
5 years (18250 time-steps). Red lines represent activated unrecoverable damage, blue lines represent recoverable damage and black lines total
damage (recoverable + unrecoverable). Some spikes on the recoverable damage curves are present. However such damage is usually recovered
in healthy patients, as at the end of simulations the total damage is mostly 0.
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Figure 5 Damage progression vs time in hill patients. Simulation of eight randomly-selected hill virtual patients. Simulation time is 5 years
(18250 time-steps). Red lines represent activated unrecoverable damage, blue lines represent recoverable damage and black lines total damage
(recoverable + unrecoverable). In this case it is possible to observe more frequent spikes in the reversible damage curves. Furthermore
unrecoverable damage (that can be correlated with the appearing MS plaques) is also present.
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Figure 6 Spatial plot at the end of the simulation in healthy patients. Figure gives a spatial representation of the simulated scenario (i.e. a
small portion of brain tissues) at the end of the simulation for eight randomly-selected healthy virtual patients. Light green patches represent
non-damaged areas. Dark green patches (see for example plot (c)) represent areas with recoverable damage. Black patches (see for example plot
(b), yellow circle) represent areas with unrecoverable damage. Red dots represent activated Teff and blue dots represent activated Treg. Green
dots represent viruses. White and black dots represent resting Teff and Treg, respectively.
Figure 7 Spatial plot at the end of the simulation in hill patients. Figure gives a spatial representation of the simulated scenario (i.e.
a small portion of brain tissues) at the end of the simulation for eight randomly-selected healthy virtual patients. Light green patches represent
non-damaged areas. Dark green patches represent areas with recoverable damage. Black patches represent areas with unrecoverable damage.
Red dots represent activated Teff and blue dots represent activated Treg. Green dots represent viruses. White and black dots represent resting
Teff and Treg, respectively.
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integrate the damage done by demyelination and role of
Treg cells in a quantitative way to correlate the disfunc-
tion of Treg cells and demyelinated area as shown in a
recent study [57].
MS is a disease that involves practically all the immune
system machinery, both at cellular, molecular and
sub-molecular level. A detailed model would require a
specialized framework and for this reason would be com-
putationally expensive. The current version of Netlogo is
probably not suitable to this purpose. We are working in
this direction using a general framework for the immune
system developed by us for other pathologies. Progress in
this direction will be published in due course.
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